Group 1 - The core point of the article is that China Biologic Products announced the acquisition of 100% equity in Hejia for a total price of 1.2 billion yuan, with approximately 1.1 billion yuan paid in cash and the remaining 97 million yuan paid in new shares [1] - Hejia is a clinical-stage biotech company focused on siRNA technology, currently having four clinical-stage projects targeting Lp(a), ApoC3, THRbeta, and HBV, along with over ten preclinical candidates [1] - This acquisition marks the third transaction by China Biologic Products in two years, and Goldman Sachs believes that as siRNA technology becomes an important innovation model for chronic disease treatment, this acquisition will enhance the company's R&D pipeline in cardiovascular, metabolic, and liver disease areas, creating synergies with existing products [1] Group 2 - Goldman Sachs has given China Biologic Products a "Buy" rating with a target price of 6.19 HKD [1]
大行评级｜高盛：中生制药收购赫吉亚将加强研发管线 评级“买入”
Ge Long Hui·2026-01-15 05:45